nach oben

Erschienen in:

01.12.2018 | Original paper

Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk

verfasst von: Rosie Cornish, Anne Cathrine Staff, Andy Boyd, Debbie A. Lawlor, Steinar Tretli, Gary Bradwin, Thomas F. McElrath, Marianne Hyer, Robert N. Hoover, Rebecca Troisi

Erschienen in: Cancer Causes & Control | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Breast cancer risk associated with pregnancy characteristics may be mediated by maternal hormones or angiogenic factors.

Methods

We conducted a prospective breast cancer case-control study among women in the Avon Longitudinal Study of Parents and Children (ALSPAC) and Norwegian Mother and Child Cohort Study (MoBa) related to maternal pregnancy prolactin (n = 254 cases and 374 controls), placental growth factor (PlGF, n = 252 and 371), soluble fms-like tyrosine kinase-1 (sFlt-1, n = 118 and 240) and steroid hormone concentrations (ALSPAC only, n = 173 and 171). Odds ratios (OR) and 95% confidence intervals (CI) for a 1 SD change in analytes were estimated using unconditional logistic regression with matching factors (cohort, mother’s birth year, serum/plasma, blood collection timing) and gestational age.

Results

Breast cancer ORs (95% CI) were 0.85 (0.51–1.43) for estradiol, 0.86 (0.67–1.09) for testosterone, 0.89 (0.71–1.13) for androstenedione, 0.97 (0.71–1.34) for hCG, 0.93 (0.75, 1.15) for prolactin, 1.00 (0.78–1.27) for PlGF and 1.91 (1.00–3.65 ALSPAC) and 0.94 (0.73–1.21 MoBa) for sFlt-1, and were similar adjusting for potential confounders. Results were similar by blood collection timing, parity, age at first birth or diagnosis, and time between pregnancy and diagnosis.

Conclusion

These data do not provide strong evidence of associations between maternal hormones or angiogenic factors with subsequent maternal breast cancer risk.

Nur mit Berechtigung zugänglich

Medina D (2005) Mammary developmental fate and breast cancer risk. Endocr Relat Cancer 12:483–495CrossRef

Schedin P (2006) Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 6:281–291CrossRef

Key T, Appleby P, Barnes I, Reeves G, Endogenous, Hormones & Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616CrossRef

Richardson BE, Hulka BS, Peck JL, Hughes CL, van den Berg BJ, Christianson RE, Calvin JA (1998) Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 148:719–727CrossRef

Melbye M, Wohlfahrt J, Lei U, Nørgaard-Pedersen B, Mouridsen HT, Lambe M, Michels KB (2000) Alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence. J Natl Cancer Inst 92:1001–1005CrossRef

Peck JD, Hulka BS, Poole C, Savitz DA, Baird D, Richardson BE (2002) Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev 11:361–368PubMed

Lukanova A, Toniolo P, Zeleniuch-Jacquotte A, Grankvist K, Wulff M, Arslan AA, Afanasyeva Y, Johansson R, Lenner P, Hallmans G et al (2006) Insulin-like growth factor I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomark Prev 15:2489–2493CrossRef

Lukanova A, Andersson R, Wulff M, Zeleniuch-Jacquotte A, Grankvist K, Dossus L, Afanasyeva Y, Johansson R, Arslan AA, Lenner P et al (2008) Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case-control study. Am J Epidemiol 168:1284–1291CrossRef

Lukanova A, Surcel HM, Lundin E, Kaasila M, Lakso HA, Schock H, Husing A, Kaaks R, Koskela P, Grankvist K et al (2012) Circulating estrogens and progesterone during primiparous pregnancies and risk of maternal breast cancer. Int J Cancer 130:910–920CrossRef

10.

Vatten LJ, Romundstad PR, Jenum PA, Eskild A (2009) Angiogenic balance in pregnancy and subsequent breast cancer risk and survival: a population study. Cancer Epidemiol Biomark Prev 18:2074–2078CrossRef

11.

Jeffreys M, Northstone K, Holly J, Emmett P, Gunnell D (2011) Levels of insulin-like growth factor during pregnancy and maternal cancer risk: a nested case-control study. Cancer Causes Control 22:945–953CrossRef

12.

Toniolo P, Grankvist K, Wulff M, Chen T, Johansson R, Schock H, Lenner P, Hallmans G, Lehtinen M, Kaaks R et al (2010) Human chorionic gonadotropin in pregnancy and maternal risk of breast cancer. Cancer Res 70:6779–6786CrossRef

13.

Toriola AT, Lundin E, Schock H, Grankvist K, Pukkala E, Chen T, Zeleniuch-Jacquotte A, Toniolo P, Lehtinen M, Surcel HM et al (2011) Circulating insulin-like growth factor-I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomark Prev 20:1798–1801CrossRef

14.

Toriola AT, Tolockiene E, Schock H, Surcel HM, Zeleniuch-Jacquotte A, Wadell G, Toniolo P, Lundin E, Grankvist K, Lukanova A (2014) Free β-human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer. Future Oncol 10:377–384CrossRef

15.

Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso H, Tanner M, Kallio R, Joensuu H, Grankvist K et al (2014) Early pregnancy sex steroids and maternal breast cancer: a nested case-control study. Cancer Res 74:6958–6967CrossRef

16.

Fortner RT, Tolockiene E, Schock H, Oda H, Lakso H, Hallmans G, Kaaks R, Toniolo P, Zeleniuch-Jacquotte A, Grankvist K et al (2017) Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case-control study in the Northern Sweden maternity cohort. Breast Cancer Res 19:82CrossRef

17.

Cohn BA, Cirillo PM, Hopper BR, Siiteri PK (2017) Third trimester estrogens and maternal breast cancer: prospective evidence. J Clin Endocrinol Metab 102:3739–3748CrossRef

18.

Troisi R, Weiss HA, Hoover RN, Potischman N, Swanson CA, Brogan DR, Coates RJ, Gammon MD, Malone KE, Daling JR et al (1998) Pregnancy characteristics and maternal risk of breast cancer. Epidemiology 9:641–647CrossRef

19.

Innes KE, Byers TE (1999) Preeclampsia and breast cancer risk. Epidemiology 10:722–732CrossRef

20.

Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R (2002) Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer 87:971–973CrossRef

21.

Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA (2005) Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 57:1R–7RCrossRef

22.

Aagaard-Tillery KM, Stoddard GJ, Holmgren C, Lacoursiere DY, Fraser A, Mineau GP, Varner MW (2006) Preeclampsia and subsequent risk of cancer in Utah. Am J Obstet Gynecol 195:691–699CrossRef

23.

Troisi R, Braekke K, Harsem NK, Hyer M, Hoover RN, Staff AC (2008) Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. Am J Obstet Gynecol 199:653.e1–653.e10CrossRef

24.

Redman CW, Staff AC (2015) Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol 213:S9.e1–S9.e11CrossRef

25.

Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, Molloy L, Ness A, Ring S, Davey Smith G (2013) Cohort profile: the ‘children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol 42:111–127CrossRef

26.

Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, Henderson J, Macleod J, Molloy L, Ness A et al (2013) Cohort profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol 42:97–110CrossRef

27.

Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, Handal M, Haugen M, Hoiseth G, Knudsen GP et al (2016) Cohort profile update: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol 45:382–388CrossRef

28.

Mabie J, Riley T, Marcus PM, Black A, Rozjabek H, Yu K, Young M, Austin J, Rathmell J, Williams C et al (2015) Data processing and analytic support in the PLCO cancer screening trial. Rev Recent Clin Trials 10:233–237CrossRef

29.

Troisi R, Ganmaa D, dos Santos Silva I, Davaalkham D, Rosenberg PS, Rich-Edwards J, Frasier L, Houghton L, Janes C, Stanczyk F et al (2014) The role of hormones in the differences in the incidence of breast cancer between Mongolia and the United Kingdom. PLoS ONE 9:e114455CrossRef

30.

Paltiel L, Haugan A, Skjerden T, Harbak K, Bækken S, Stensrud NK, Knudsen GP, Magnus P (2014) The biobank of the Norwegian Mother and Child Cohort Study—present status. Nor J Epidemiol 24:29–35CrossRef

31.

Royston P, Ambler G, Sauerbrei W (1999) The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 28:964–974CrossRef

32.

Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso H, Tanner M, Kallio R, Joensuu H, Korpela J et al (2017) Human chorionic gonadotropin does not correlate with risk for maternal breast cancer: results from the finnish maternity cohort. Cancer Res 77:134–141CrossRef

33.

Wang M, Wu X, Chai F, Zhang Y, Jiang J (2016) Plasma prolactin and breast cancer risk: a meta-analysis. Sci Rep 6:25998CrossRef

34.

Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683CrossRef

35.

Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso H-Å, Idahl A, Lehtinen M, Surcel H-M, Fortner RT (2016) Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth 16:146CrossRef

36.

Neville MC, McFadden TB, Forsyth I (2002) Hormonal regulation of mammary differentiation and milk secretion. J Mamm Gland Biol Neoplasia 7:49–66CrossRef

37.

Pepe G, Albrecht E (2008) Steroid endocrinology of pregnancy. Glob Libr Women’s Med. ISSN: 1756–2228. https://doi.org/10.3843/GLOWM.10311

38.

Fuhrman BJ, Xu X, Falk RT, Hankinson SE, Veenstra TD, Keefer LK, Ziegler RG (2010) Stability of 15 estrogens and estrogen metabolites in urine samples under processing and storage conditions typically used in epidemiologic studies. Int J Biol Mark 25:185–194CrossRef

Titel: Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk
verfasst von: Rosie Cornish
Anne Cathrine Staff
Andy Boyd
Debbie A. Lawlor
Steinar Tretli
Gary Bradwin
Thomas F. McElrath
Marianne Hyer
Robert N. Hoover
Rebecca Troisi
Publikationsdatum: 01.12.2018
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 1/2019
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-018-1100-6

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Active and secondhand smoke exposure throughout life and DNA methylation in breast tumors

Reproductive and menopausal factors and risk of second primary breast cancer after in situ breast carcinoma

Habitual recreational physical activity is associated with significantly improved survival in cancer patients: evidence from the Roswell Park Data Bank and BioRepository

The rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patients

Potential protein markers for breast cancer recurrence: a retrospective cohort study

Pre- and perinatal factors and incidence of breast cancer in the Black Women’s Health Study

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie